Government vows vaccine push, says will get 217 crore shots from August to December. Setting up its own vaccination campaign for about 95 crore 18-plus people, the center on Thursday said India should be able to acquire an estimated 217 crore anti-Covid guns between August and December.
In the meantime, prices of 51.6 crore have been ordered to meet demand until July. This includes doses of 35.6 crore (including 1 crore from the GAVI Covax Center) received by the Center, and 16 crore received directly by hospitals and private hospitals. Responding to concerns about declining vaccinations due to a shortage of 18-44-year-olds and the increase in plaques in the 45 plus category, the government said the pace would take and access to vaccines made in India would increase sharply as foreign vaccines could be available in the next few months.
“She looks hopeful. Yes, this is hopeful. Is there a risk that it may not happen. Possibly, but arrangements are in place. These are promising vaccines, ”said Dr V K Paul, a member of Niti Aayog and head of the National Expert Group for Vaccine Administration for Covid-19 (NEGVAC). The total number of available doses will continue to rise to 300 crores by the end of the first quarter of 2022, said Dr Paul. He said the ratings were based on the results of the lab and the case. Of the total order of the 35.6 crore prices set by the Agency to date, 7.6 crores have been received and used, with 86% of the 12 crore values obtained in phase 2 received and the rest will be by the end of this month. Between May and July, an additional 16 crore doses will be offered as part of the purchase of phase 3 of the Center. In May alone, about 7.3 crore doses were obtained through the center, private hospitals.
A major move is expected between August and December, when the Serum Institute of India is expected to produce about 75 crore prices, as well as 55 crore prices at Covaxin – now also made in three phases of the public sector outside Bharat Biotech – estimated to be available. Local production of Russian Sputnik V, currently imported, will begin in July and 15.6 crore volumes are expected to be available for use in the area within the specified period.
In addition to this, the government is considering a recurrent Biological E vaccine, in partnership with Baylor Medical College in the US, to provide 30 crore doses, in addition to vaccines from Cadila Healthcare, Gennova Pharma and Bharat Biotech nasal vaccine employee. Speculations include Novavax, which will be made by SII in India. This guess is “obligatory” and has been shown by companies, says Dr. Paul.
He added saying that they are proud to announce that with more than 2 billion doses over a five-month period will be made in India for the people of India. So there should be no two options so the vaccine will be available to all as they move forward.
Emphasizing the asymmetry in the demand and supply of vaccines, Dr Paul said the new policy that allows countries and private companies to participate in procurement is a response to popular needs and the country’s insistence that it means something. This distribution was divided between the center that kept 50% production in the 45-plus group and divided the rest between the provinces and private hospitals. In the face of a global epidemic, prioritization of drug seekers is needed, he said.
The government is also in regular talks with foreign vaccine manufacturers such as Pfizer, Moderna and J&J asking them to make their drugs available in India, said Dr Paul. He also said that he would like these companies to bring their drugs to India, cooperate with Indian companies, transfer technology and make them here. Under the new policy, the channel is open and will support them.
The government has also relaxed the regulations for the regulation of imported and developed vaccines that have already been adopted by trusted international regulators such as the USFDA and the UK MHRA etc.